All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Eli Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Results from the 5‑year follow-up of the randomized, open-label, phase III GAIA/CLL13 (NCT02950051) trial, evaluating fixed-duration venetoclax combinations (venetoclax + rituximab [RV], venetoclax + obinutuzumab [GV], and GV + ibrutinib [GIV]) vs chemoimmunotherapy (CIT) in 926 fit patients with previously untreated chronic lymphocytic leukemia (CLL) without TP53 aberrations, were published in Blood by Fürstenau et al. The co-primary endpoints were the rate of undetectable measurable residual disease (uMRD) in peripheral blood at Month 15 and investigator-assessed progression-free survival (PFS). Results from the GAIA/CLL13 study have previously been published on the Lymphoma Hub.
Key data: At a median follow-up of 63.8 months, 5‑year PFS rates were 81.3%, 69.8%, 57.4%, and 50.7% in the GIV, GV, RV, and CIT groups, respectively. Five-year overall survival (OS) rates were 94.3%, 93.6%, 94.7%, and 90.7%, respectively. Mean change from baseline in global health status (GHS) remained above the minimal important difference (MID) from Month 6 to follow-up in the RV and GV arms, with median times until improvement (TUI) of 5.8 and 5.9 months, respectively. The first mean change from baseline above MID was observed at 15 months in the GIV arm and at 24 months in the CIT arm.
Key learning: Results suggest that fixed-duration GV and GIV improve PFS vs CIT and RV. Treatment with GV or RV resulted in greater and more rapid quality of life (QoL) improvements compared with CIT. Clinically meaningful improvements in QoL occurred later with GIV than with GV and RV, likely due to a higher treatment-related symptom burden. These results support the use of venetoclax-based therapy as a treatment option for patients with previously untreated CLL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average vein-to-vein time when treating patients with DLBCL with a reimbursed CAR T-cell therapy (from apheresis to infusion)?